Associated Papers
Genomic Landscape of Susceptibility to Severe COVID-19 in the Slovenian Population.
Kovanda A et al.
International Journal of Molecular Sciences, 2024
39062917 (PubMed )
Supplement: ijms-25-07674-s001.zip › Supplementary_table_3.xlsx › ACMG_classified_variants
Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.
Henderson GJ et al.
Antimicrobial Agents and Chemotherapy, 2012
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V et al.
Antimicrobial Agents and Chemotherapy, 2005
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W et al.
Journal of Virology, 2002
Select a paper to view details